Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Pfizer Inc.

PFENYSEPharmaWILMINGTON, US-DE, USLarge capWebsite ↗
  • S&P 500
  • S&P 100
  • Russell 1000

What Pfizer Inc. is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to June 28, 2026: $63.7 billion, down 0.2% from a year earlier.SEC EDGAR filings (XBRL)
  • Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 28, 2026: $11.0 billion, down 12% from a year earlier.SEC EDGAR filings (XBRL)
  • Capital expenditure over the four quarters to June 28, 2026: $2.42 billion, down 12% from a year earlier.SEC EDGAR filings (XBRL)
  • Long-term debt issued in the fiscal year to December 31, 2025: $9.68 billion.SEC EDGAR filings (10-K)
  • Latest earnings call or results release (August 4, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.80 of 1.Palanor Discourse
  • Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 4 held.Guidance Ledger (8-K results releases)
  • Latest annual report (filed February 26, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net buyers in Q3 2026: $2.9 million on the open market.SEC Form 4
  • 2,846 institutional managers reported a position at June 30, 2026 (−120 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 29 (41 a year earlier).U.S. Department of Labor (OFLC)
  • Headlines in the last 30 days: 13, of which 2 read positive and 3 negative.Palanor headline tone

Risk events (12 months): 1 — latest OSHA inspection, Dec 2, 2025 →

Company Posture

How Company Posture is measured →

What Pfizer Inc. is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.

Retrenching · Confident

Expanding ↔ Retrenching

Retrenching

RetrenchingExpanding

Confident ↔ Hedging

Confident

HedgingConfident

Pressure

Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).

Credit

How these are built →

Pfizer Inc.'s borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.

Debt on the balance sheet

$63.2B

  • Due within a year $2.7B
  • Longer term $60.5B
  • Default point $32.9B (short + ½ long)

Finance leases included · Jun 28, 2026 filing

Bonds priced, last 12 months

$6.0B

U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.

PricedAmountCouponMaturesSpreadYield
Nov 18, 2025$1.25B4.875%2035 (10y)+75bp4.877%
Nov 18, 2025$500M5.600%2055 (30y)+88bp5.624%
Nov 18, 2025$500M5.700%2065 (40y)+100bp5.749%
Nov 18, 2025$500MSOFR + 50bp2027 (2y)——
Nov 18, 2025$1B3.875%2027 (2y)+30bp3.881%
Nov 18, 2025$1B4.200%2030 (5y)+52bp4.218%
Nov 18, 2025$1.25B4.500%2032 (7y)+65bp4.537%
May 14, 2025€800M4.250%2045 (20y)+122bp4.290%
May 14, 2025€1B3.250%2032 (7y)+94bp3.370%
May 14, 2025€750M3.875%2037 (12y)+106bp3.890%
May 14, 2025€750M2.875%2029 (4y)+75bp2.901%

From the pricing term sheets Pfizer Inc. filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Pfizer Inc.: free cash flow, trailing twelve months

Operating cash flow minus capital expenditure, $ billions, from SEC filings

$11.0BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Pfizer Inc.: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Pfizer Inc.: revenue, trailing twelve months

$ billions, from SEC filings

$63.7BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Pfizer Inc.: share buybacks by fiscal year

Cash paid to repurchase common stock, $ billions, from the 10-K

$0.0BData to Dec 2024
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Pfizer Inc.: debt issued and repaid by fiscal year

Long-term debt, $ billions, from the 10-K

Data to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Pfizer Inc.: debt due within a year and cash

At each balance-sheet date, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Pfizer Inc.: interest coverage

Operating income ÷ interest expense, trailing twelve months, from SEC filings

2.6Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Pfizer Inc.: guidance raised minus lowered

Guidance Ledger statements by quarter

1.0Data 23 days ago
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Pfizer Inc.: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.60Data to Aug 2026
ImageDataPalanor calculation
Business

Pfizer Inc.: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.80Data to Aug 2026
ImageDataPalanor calculation
Business

Pfizer Inc.: risk factors added per annual report

New Item 1A risk factors in each 10-K

0.00Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Pfizer Inc.: H-1B filings certified

Labor Condition Applications by quarter received

29.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Pfizer Inc.: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

$2.9MData 23 days ago
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Pfizer Inc.: institutional holders

Managers reporting a position on Form 13F, by quarter

2,846Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

News

Business

Pfizer Inc.: headline tone

Net share of positive headlines, trailing 28 days, −1 to +1

−0.08Data 6 days ago
ImagePalanor calculation from news headlines (tone words only)

In the news

Headlines that name Pfizer Inc., with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days
13 headlines
15% positive · 23% negative
90 days
20 headlines
20% positive · 15% negative

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 20, 2026Lobbying
    Lobbying report (MARSHALL & POPP, LLC)third_quarter 2026 · $0.1 million
  2. Oct 20, 2026Lobbying
    Lobbying report (THE DUBERSTEIN GROUP INC.)third_quarter 2026 · $0.1 million
  3. Oct 20, 2026Lobbying
    Lobbying report (WILLIAMS AND JENSEN, PLLC)third_quarter 2026 · $0.1 million
  4. Oct 20, 2026Lobbying
    Lobbying report (PFIZER INC.)third_quarter 2026 · $3.6 million
  5. Oct 20, 2026Lobbying
    Lobbying report (MILLER STRATEGIES, LLC)third_quarter 2026 · $0.1 million
  6. Oct 20, 2026Lobbying
    Lobbying report (FEDERAL HEALTH POLICY STRATEGIES)third_quarter 2026 · $0.1 million
  7. Oct 20, 2026Lobbying
    Lobbying report (BGR GOVERNMENT AFFAIRS)third_quarter 2026 · $0.1 million
  8. Oct 20, 2026Lobbying
    Lobbying report (AKIN GUMP STRAUSS HAUER & FELD)third_quarter 2026 · $0.1 million
  9. Oct 20, 2026Patent
    Patent granted: CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTORUS 12767646
  10. Oct 13, 2026Patent
    Patent granted: Stable Immediate Release Tablet and Capsule Formulations of 1-((2S,5R)-5-((7H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino)-2-Methylpiperidin-1-YL)Prop-2-EN-1-OneUS 12758554
  11. Oct 13, 2026Patent
    Patent granted: Novel SIK InhibitorsUS 12760019
  12. Oct 13, 2026Patent
    Patent granted: SYSTEM AND METHOD FOR NEEDLE HIDING IN INJECTORSUS 12758718
  13. Sep 29, 2026Patent
    Patent granted: KRAS G12D INHIBITORSUS 12747253
  14. Jun 18, 20268-K
    Director or officer changeItem 5.02
  15. Apr 27, 20268-K
    Shareholder vote resultsItem 5.07
  16. Apr 7, 2026Federal award
    Federal award from Department of Defense$36.5 million
  17. Feb 26, 202610-K
    Annual report (10-K)0 risk factors added, 0 removed
  18. Dec 2, 2025Risk event
    OSHA complaint inspection: PFIZER INC.OSHA
  19. Aug 13, 2025Risk event
    OSHA referral inspection: PFIZER INCOSHA
  20. Apr 29, 20258-K
    Exit or restructuring costsItem 2.05
  21. Apr 28, 20258-K
    Shareholder vote resultsItem 5.07
  22. Mar 17, 2025Risk event
    OSHA programmed inspection: PFIZER INCOSHA
  23. Feb 27, 202510-K
    Annual report (10-K)0 risk factors added, 0 removed
  24. Jan 27, 2025Risk event
    OSHA complaint inspection: PFIZER, INC.OSHA
  25. Oct 23, 2024Risk event
    OSHA referral inspection: PFIZER INC.OSHA
  26. Feb 22, 202410-K
    Annual report (10-K)3 risk factors added, 36 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Merck & Co. MRK$66.6B$16.1BJun 30, 2026
Eli Lilly and Company LLY$79.7B—Jun 30, 2026
Johnson & Johnson JNJ$97.9B$22.2BJun 28, 2026
AbbVie Inc. ABBV$64.4B$18.2BJun 30, 2026
HCA Healthcare HCA$76.4B$7.9BMar 31, 2026
Bristol Myers Squibb BMY$49.2B$11.4BJun 30, 2026
Thermo Fisher Scientific TMO$46.3B$7.3BJun 27, 2026
Abbott Laboratories ABT$45.1B$7.4BMar 31, 2026

Identity

SEC CIK
78003
LEI
765LHXWGK1KXCLTFYQ30
Wikidata
Q206921
SAM UEI
MHBQULRMEEJ5
SAM UEI
DP7KL2MKRSB5

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.